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Thyroid hormone withdrawal (THW) for postoperative radioiodine adjuvant therapy or diagnostic radioiodine whole body scan
in patients with differentiated thyroid cancers results in acute thyroid hormone deficiency and abnormal lipid profiles. To better
clarify the clinical pattern of dyslipidemia occurring after THW, we retrospectively analyzed the association between serum total
cholesterol level after THW and various clinical factors in a total of 61 patients who underwent total thyroidectomy due to papillary
thyroid cancers from January 2010 to March 2012, in Severance Hospital, Seoul, Korea. Preoperative baseline total cholesterol was
significantly correlated with post-THW total cholesterol level; however, age, gender, or elevated TSH level after THW itself was not
correlated with post-THW total cholesterol level. A significant correlation between preoperative measured BMI and post-THW
total cholesterol level was found (𝑟 = 0.263, 𝑃 = 0.041). In multiple logistic analysis, BMI was an independent determining factor
of post-THW total cholesterol level (𝑃 = 0.012).
1. Introduction
Hypothyroidism causes adverse effects on lipoproteinmetab-
olism.The association between thyroid function and dyslipi-
demia is well demonstrated not only in overt hypothyroidism,
but also in low normal thyroid function with TSH level
within normal range [1]. Patients with hypothyroidism are
known to have significantly higher serum total cholesterol,
low-density lipoprotein cholesterol (LDL-C), and triglyceride
levels compared to healthy population. In addition, carotid
intima-media thickness and flow-mediated vasodilatation,
which are surrogated markers of atherosclerosis and vascular
endothelial dysfunction, are also known to be associated with
thyroid function, even when TSH level is within normal
reference range [2–5].
Although dyslipidemia and atherosclerosis are both well-
definedmajor risk factors of cardiovascular diseases, whether
patients with high or high normal TSH level are definitely
at an increased risk of cardiovascular diseases is still under
controversy [6, 7]. The possible influence of various clini-
cal factors related to cardiovascular diseases, such as age,
gender, and body mass index (BMI), is one of the reasons
contributing to the uncertainty of the association [6, 8].
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This suggests that a variety of influencing factors must be
taken into account when approaching dyslipidemia—and
furthermore, cardiovascular risk factors—accompanied by
hypothyroidism.
When performing postoperative radioiodine adjuvant
therapy or diagnostic radioiodinewhole body scan in patients
with differentiated thyroid cancers (DTC), a TSH elevation
higher than 30mU/L achieved through thyroid hormone
withdrawal (THW) (withdrawal of levothyroxine (L-T4)) is
required in most cases [9]. THW inevitably results in acute
thyroid hormone deficiency in patients who have undergone
total thyroidectomy, and abnormal lipid profiles, such as
hypercholesterolemia, are accompanied in majority of such
cases. Several previous studies have investigated hypothyroid
symptoms and metabolic effects following THW in patients
with DTC; however, none has elucidated the factors influ-
encing post-THW dyslipidemia. A subgroup of such patients
actually does not develop dyslipidemia after THW [10–13].
This study retrospectively analyzed the association
between serum cholesterol level and various clinical factors
in the setting of TSH elevation in order to better clarify the
clinical pattern of dyslipidemia occurring after THW inDTC
patients and, as a result, found that BMI is an independent
factor determining post-THW serum cholesterol level.
2. Materials and Methods
2.1. Study Subjects and Clinical Data. A total of 142 consec-
utive patients diagnosed with papillary thyroid carcinoma
with intermediate recurrence risk based on 2009 American
Thyroid Association (ATA) guideline and who underwent
postoperative 1.1 GBq radioiodine (131-I) remnant ablation
(RRA) in Endocrinology Cinic, Severance Hospital, Seoul,
Korea, from January 2010 toMarch 2012, were retrospectively
reviewed. Among them, the data of 61 patients who con-
sented to the measurement of lipid profiles following THW
were selectively included in the analysis. The lipid profiling
was performed simultaneously with stimulated thyroglobulin
(Tg) assay when the patients visited the endocrinology clinic
after a 3-week THW regime. All subjects who had histories of
diabetes mellitus, use of lipid-lowering drugs, or underlying
thyroid dysfunction were excluded in the analysis.
The medical records of the patients were reviewed, and
the preoperative baseline characteristics, including age, gen-
der, BMI, various biochemical parameters measured before
and after surgery, and postoperative RRA, were retrospec-
tively analyzed.This retrospective study was approved by our
Institutional Review Board, and informed consent was not
required.
As per postoperative follow-up protocol for DTC in our
institution, the patients received low-dose RRA 3 months
after undergoing total thyroidectomy, and TSH-suppressive
dose of L-T4 (150 𝜇g/d) was administered for 3 months after
the surgery. After 4 weeks of THW, thyroid function test
(TFT) and lipid profilingwere performed in conjunctionwith
measurement of Tg, anti-Tg antibody immediately before the
oral administration of 1.1 GBq I-131. A postablation whole
body scan was performed 48 h after administration of I-131,
and, thereafter, TSH-suppressive dose of L-T4 was begun
again in all patients.
Following postoperative RRA, the patients visited our
endocrinology outpatient clinic approximately every six
months during immediate postoperative follow-up periods
for surveillance of recurrence and persistence of the disease.
The mean duration from the day of RRA to the first and
second follow-up visit days was 5.9 ± 1.0 and 15.9 ± 3.7
months, respectively, and a TSH-suppressive does of L-T4
(150 𝜇g/d) was maintained in all patients during this period.
In the first follow-up visit after RRA (P2), TFT and lipid
profiling were performed in all 61 subjects, and, in 41 subjects,
themeasurements were repeated in the second follow-up visit
after RRA (P3).
2.2. Thyroid Function Test and Biochemical Measurements.
Baseline TFT and biochemical parameters including plasma
glucose, uric acid, total cholesterol, triglycerides, and high-
density lipoprotein cholesterol (HDL-C) were measured
immediately before total thyroidectomy. TFT and lipid pro-
files were measured after THW for postoperative RRA and at
one or two follow-up visits thereafter.
After 12 h of fasting, all blood samples were obtained
from the patients and stored at −70∘C for subsequent assays.
Serum TSH and free T4 and T3 were measured by chemi-
luminescent microparticle immunoassay (Architect System,
Abbott Ireland Diagnostic Division, Lisnamuck, Longford,
Co. Longford, Ireland). Plasma glucose, uric acid, triglyc-
erides, total cholesterol, andHDL-C levels were assayed using
a routine Hitachi 7600 autoanalyzer (Hitachi Instruments
Service, Tokyo, Japan). Low-density lipoprotein cholesterol
(LDL-C) levels were calculated using the Friedewald formula
[14].
2.3. Statistical Analysis. Data were shown as means ± stan-
dard deviations if they were continuous variables. The
normal distribution of each variable was examined using
Kolmogorov-Smirnov test.The differences between themean
level of baseline total cholesterol of subjects and that of
each serial time point were validated through paired sam-
ple t-test. Spearman correlations were used to examine
the relationships between total cholesterol level after THW
and age, gender, BMI, TSH level, LDL-C level after THW,
and total cholesterol at other time points. Comparison of
categorical variables between BMI groups was performed
using chi-square test and Fisher’s exact test (two-tailed), as
is appropriate. To investigate the association between BMI
and other clinical parameters including age, gender, and
post-THW total cholesterol more accurately, we employed a
logistic regression analysis. 𝑃 values < 0.05 were considered
statistically significant for all tests. All calculations and
statistical analyses were performed using IBM SPSS software
package for Windows (Version 20.0; IBM Corp., NY, USA).
3. Results
3.1. Changes ofThyroid Function and Lipid Profiles after THW.
The mean age of 61 subjects (M : F = 14 : 47) was 49 ± 11 yr,
and the mean BMI was 23.9 ± 3.3 kg/m2. All patients showed
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Table 1: Clinical and metabolic characteristics of the 61 patients.
Mean ± SD
Sex (M/F) 14/47
Age (yr) 49 ± 11
Body mass index (kg/m2) 23.9 ± 3.3
Preoperative total cholesterol (mg/dL) 194.8 ± 39.8
Total cholesterol elevation (mg/dL) 54.2 ± 42.6
TSH (LT4-off) (mU/L) 82.4 ± 41.3
T3 (LT4-off) (ng/mL) 0.5 ± 0.3
Free T4 (LT4-off) (ng/dL) 0.5 ± 0.2
TSH: thyroid stimulating hormone.
serum TSH level greater than 30 mU/L (82.4 ± 41.3 mU/L)
after a 4-week THW regimen (Table 1). We first compared
TFT and lipid profiles measured across four time points
(P0-3): immediate preoperative period (P0), the day of 131-
I administration after THW (P1), the first follow-up visit
after RRA (P2), and the second follow-up visit after RRA
(P3) (Table 2). The mean total cholesterol level after THW
(P1) significantly increased compared to that at preoperative
baseline (P0) (249.1 ± 58.0mg/dL versus 194.8 ± 39.8mg/dL,
𝑃 < 0.001), but at follow-up visit after RRA and LT-
4 readministration (P2), it returned to baseline level (P0)
(Figure 1). Plasma LDL-C also increased to 167.7± 52.0mg/dL
at P1, during which TSH elevation was also observed, but
returned to within normal range thereafter. Plasma TG and
HDL-C did not exceed the normal range at P1, P2, or P3.
All the serum triglycerides levels measured at different three
time points were below 400mg/dL. The maximal value of
triglycerides in study subjects was 340mg/dL (P1), 239mg/dL
(P2), and 298mg/dL (P3), respectively.
3.2. Correlation between BMI and Total Cholesterol Level
after THW. A simple correlation analysis between post-
THW total cholesterol (P1) and various clinical parameters,
including BMI, age, gender, elevated TSH level after THW(L-
T4-off), and preoperative baseline total cholesterol level, was
performed (Table 3). As a result, preoperative baseline total
cholesterol showed significant correlation with post-THW
cholesterol, as expected; however, age, gender, or elevated
TSH level afterTHWitself was not correlatedwith post-THW
total cholesterol (P1). Interestingly, a significant correlation
between preoperative BMI and post-THW total cholesterol
was found (𝑟 = 0.263,𝑃 = 0.041). Post-THWtotal cholesterol
(P1) was also associated with post-THW calculated LDL-
C. The level of total cholesterol measured at follow-up visit
showed correlation only at the first follow-up visit after RRA
(P2).
3.3. Serial Changes of Correlation between BMI and Total
Cholesterol before and after THW. To further clarify the
association between BMI and total cholesterol in thyroidec-
tomized patients, the correlation between total cholesterol
and BMI at each of the four time points was evaluated
(Figure 2). While BMI was not correlated with total choles-
terol level at baseline (P0), the correlation appeared not only
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Figure 1: The serial change of mean total cholesterol levels.
at P1, but also at P2, which then disappeared at the second
follow-up visit completed at 15.9 ± 3.7 months after RRA.
3.4. Different Changes of Total Cholesterol after THW accord-
ing to BMI of 23 kg/m2. We stratified the patients as either
normal weight (n = 21) or overweight group (n = 40) based
on the criteria of BMI of 23 kg/m2, and their demographics,
baseline biochemical parameters, and the changes of lipid
profiles after THWwere compared (Table 4).The overweight
group was older than normal weight group (53.1 ± 9.2 vs. 39.9
± 10.5 yr, 𝑃 = 0.001), but there was no gender difference
between the two groups. Intriguingly, the two groups did not
show a significant difference in total cholesterol measured
at baseline (P0) or at post-RRA follow-up visits (P2 and
P3). The two groups significantly differed only in post-THW
total cholesterol and LDL-C level (P1). In other words, the
overweight group had the greater post-THW total cholesterol
and LDL-C level compared to normal-weight group.
3.5. BMI as an Independent Determining Factor of Total
Cholesterol Level after THW. Finally, we performed multiple
logistic analyses with post-THW total cholesterol level as a
dependent variable (Table 5), which foundBMI to be an inde-
pendent determining factor of post-THW total cholesterol
level along with preoperative baseline total cholesterol level
and elevated TSH level following THW (𝑃 = 0.012).
4. Discussion
Due to the rising incidence of thyroid cancers, much interest
has been raised regarding the possible metabolic effects or
long-term health outcomes resulting from thyroid hormonal
derangement following thyroidectomy. Patients who undergo
total thyroidectomy are potentially exposed to long duration
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Table 2: Serial changes of thyroid function test results and lipid profiles after thyroid hormone withdrawal.
P0 (𝑛 = 61) P1 (𝑛 = 61) P2 (𝑛 = 61) P3 (𝑛 = 41)
TSH (mU/L) 1.6 ± 1.0 82.4 ± 41.3 0.3 ± 1.1 0.2 ± 0.4
T3 (ng/mL) 1.1 ± 0.1 0.5 ± 0.3 1.1 ± 0.2 1.1 ± 0.1
Free T4 (ng/dL) 1.1 ± 0.2 0.5 ± 0.2 1.7 ± 0.4 1.5 ± 0.3
Total cholesterol (mg/dL) 194.8 ± 39.8 249.1 ± 58.0 186.8 ± 31.4 179.4 ± 34.2
Triglyceride (mg/dL) 129.8 ± 54.6 118.4 ± 56.1 115.7 ± 63.4
HDL-C (mg/dL) 56.3 ± 13.0 49.6 ± 9.6 51.1 ± 10.1
LDL-C (mg/dL) 167.7 ± 52.0 113.9 ± 28.6 103.0 ± 30.8
Follow-up duration (months) N/C 5.9 ± 1.0 15.9 ± 3.7
TSH: thyroid stimulating hormone; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
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Figure 2: Relationship between BMI and cholesterol levels.
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Table 3: Correlation between various clinical parameters and serum
cholesterol level after thyroid hormone withdrawal.
Cholesterol after THW
𝑟 𝑃 value
BMI (kg/m2) 0.263 0.041
Age (yr) 0.204 0.115
Gender 0.035 0.791
TSH (LT4-off) (mU/L) 0.168 0.196
Preoperative cholesterol (mg/dL) 0.685 0.001
F/U cholesterol (1) (mg/dL) 0.274 0.036
F/U cholesterol (2) (mg/dL) 0.124 0.439
LDL-C (LT4-off) (mg/dL) 0.966 0.001
TSH: thyroid stimulating hormone; F/U: follow up; LDL-C: low-density
lipoprotein cholesterol.
of subclinical or mild hyperthyroidism due to a long-term
TSH suppressive therapy; however, THW regimens required
for diagnostic or therapeutic radioiodine whole body scan
may induce acute thyroid hormone deficiency. Previous
studies have investigated the metabolic effects caused by
transient severe hypothyroidism due to THW on peripheral
target organs [10, 11]. Transient alterations of lipidmetabolism
are one of the hallmark clinical features of such THW-
induced effect, and several studies have also focused on how
changes in lipid profiles under such circumstances affect the
vascular function [13]. However, in clinical situations, the
spectrum of THW-induced changes in lipid profile is wide: in
some patients, the change is very mild, while in others, severe
hypercholesterolemia is observed. This variability is also
observed in patients in overt primary thyroid dysfunction
[15]. Nonetheless, there has been no study directly analyzing
the various associations between THW and transient dys-
lipidemia or elucidating the clinical factors influencing the
association.
Although the effects of thyroid hormone on cholesterol
metabolism are not yet fully known, it is accepted that
changes in thyroid function exert a wide range of influence
on the overall cholesterol metabolism, including its synthesis,
metabolism, and mobilization [6]. Overt hypothyroidism
is associated with tissue expression and altered activities
of various regulators participating in lipid metabolism,
including hepatic hydroxymethylglutaryl coenzymeA (HMG
CoA) reductase, LDL-C receptors, sterol regulatory element-
binding protein-2 (SREBP-2), cholesteryl ester transfer pro-
tein (CETP), hepatic lipase, lipoprotein lipase, and ATP
binding cassette transporterA1 (ABCA1) transporter [16–20].
Consequently, hypothyroid patients generally show elevated
total cholesterol and LDL-C level, as well as normal to ele-
vated HDL-C, TG, and very low density lipoprotein (VLDL)
[21].
There has been abundant clinical evidence on the rela-
tionship between hypothyroid status, abnormal lipid profile,
and the related health outcomes such as atherosclerosis and
metabolic syndrome [22–27]. On the contrary, relatively
few studies have investigated the metabolic effects of acute
thyroid hormone deficiency in DTC patients who have
to undergo THW for postoperative 131-I therapy or for
measurement of stimulated serum Tg and radioiodine whole
body scan to evaluate residual/recurrent diseases [10, 11, 13].
In a prospective study on 15 female DTC patients, Chang
et al. have reported that short-term hypothyroidism due to
THWand the consequentworsening ofmetabolic parameters
does not affect the measurements of surrogate marker for
endothelial function, such as brachial artery diameter [13].
Nonetheless, the recent surge in number of patients with
DTC, combined with mostly low mortality risk of the cases
of DTC, suggests the importance of maintaining an optimal
thyroid functional status in athyreotic patients through the
follow-up periods with a suppressive or replacement dose
of thyroid hormone, both in terms of oncologic safety and
favorable metabolic health outcome. Therefore, the clinical
features andmetabolic effects of transient severe hypothyroid
status following THW in DTC patients require further
clarification.
The occurrence of hypercholesterolemia in hypothyroid
patients cannot be explained with a single mechanism. A
combination of results of several clinical studies has found
that TSH and thyroid hormone level are both independently
associated with total cholesterol level; furthermore, various
clinical factors, including gender, age, fasting plasma glucose,
BMI, and smoking status, are also thought to exert indepen-
dent effects on total cholesterol levels [1]. In this study, we
have reported that BMI is significantly associated with total
cholesterol level measured after 4 weeks of L-T4 withdrawal
in transiently hypothyroid, athyreotic patients independently
of baseline total cholesterol level, elevated TSH level after
THW, age, and gender. To our knowledge, this is the first
study to have investigated the association between BMI and
short-term hypothyroidism-induced hypercholesterolemia
occurring during the course of postoperative surveillance in
DTC.
In this study, the mean post-THW total cholesterol and
LDL-C level exceeded the normal range only in overweight
group of patients, defined as BMI of 23 kg/m2 or higher.
The patients with normal body weight showed normal levels
of total cholesterol and LDL-C. The baseline lipid profiles
were not different between the two groups. Furthermore,
while total cholesterol level returned to preoperative baseline
level at the follow-up visits after RRA and resumption of
L-T4 replacement, the correlation between BMI and total
cholesterol level was maintained until the first follow-up
visit. Since only two patients in our patients group satis-
fied the criteria of obesity suggested by the World Health
Organization (BMI greater than 30 kg/m2), we have instead
employed a proposed BMI cutoff for overweight (23 kg/m2)
which takes into account the health risk for Asian population
[28, 29]. In a study of 18 DTC patients who underwent THW,
Huang et al. reported insulin resistance and BMI to be the
factors predictive of severity of hypothyroid symptoms after
THW[12]. Our studymay be in linewith this previous report,
and we suspect that overweight athyreotic patients can be
more vulnerable not only to hypothyroid symptoms but also
to hypothyroidism-induced abnormality of lipid profile after
THW.
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Table 4: Different serial change of lipid profile according to BMI of 23 kg/m2.
BMI < 23
(𝑛 = 21)
BMI ≥ 23
(𝑛 = 40) 𝑃 value
Mean age (yr) 39.9 ± 10.5 53.1 ± 9.2 0.001
Sex 0.244
Female (%) 18 (38.3) 29 (61.7)
Male (%) 3 (21.4) 11 (78.6)
Preoperative serum glucose (mg/dL) 88.2 ± 11.8 90.2 ± 13.9 0.571
Preoperative cholesterol (mg/dL) 186.0 ± 35.0 199.4 ± 41.8 0.224
Preoperative uric acid (mg/dL) 4.4 ± 1.2 5.1 ± 1.6 0.12
ΔCholesterol (mg/dL) 40.2 ± 37.0 61.5 ± 43.9 0.068
TSH (LT4-off) (mU/L) 88.4 ± 39.7 79.3 ± 42.3 0.427
Total cholesterol (LT4-off) (mg/dL) 226.1 ± 43.8 260.8 ± 61.2 0.015
LDL-C (LT4-off) (mg/dL) 146.1 ± 36.3 178.5 ± 55.6 0.025
HDL-C (LT4-off) (mg/dL) 56.6 ± 13.5 56.1 ± 13.0 0.899
Triglyceride (LT4-off) (mg/dL) 112.6 ± 37.3 138.5 ± 60.1 0.092
F/U cholesterol (1) (mg/dL) 176.2 ± 26.8 192.6 ± 32.5 0.059
F/U cholesterol (2) (mg/dL) 179.9 ± 25.4 179.1 ± 38.4 0.951
TSH: thyroid stimulating hormone; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; F/U: follow up.
Table 5: Multiple logistic analyses with total cholesterol level
following thyroid hormone withdrawal as a dependent variable.
Clinical parameters Regression coefficient 𝑃 value
Age (yr) −0.027 0.779
Sex −0.02 0.82
BMI (kg/m2) 0.251 0.012
Preoperative cholesterol (mg/dL) 0.639 0.001
TSH (mU/L) 0.428 0.001
BMI: body mass index; TSH: thyroid stimulating hormone.
Other past clinical studies have reported that insulin
sensitivitymay act as amodulator in the relationship between
TSH and serum lipid level in healthy euthyroid subjects and
female diabetic patients and insulin-resistant subjects are
more susceptible to the higher risk of hypercholesterolemia
as TSH level increases [30, 31]. The results of this study
imply that increased hepatic cholesterol synthesis may be
observed in DTC patients with high BMI due to relatively
elevated insulin resistance. Hypothyroidism simultaneously
suppresses hepatic cholesterol synthesis and hepatic LDL-
C receptor expression: the reduced clearance of LDL-C
overpowers the effects of low hepatic cholesterol synthesis
in hypothyroid status, resulting in hypercholesterolemia [6].
As such, we suggest that the possible increase of baseline
hepatic cholesterol synthesis following increased BMI may
be the underlying reason behind the association between
elevated BMI and post-THW hypercholesterolemia. How-
ever, the probable explanation for the association between
BMI and post-THW hypercholesterolemia is just one of
many assumptions since there was no definite evidence for
the difference of insulin resistance among the subjects in
this study. We could not obtain any surrogate parameters
regarding metabolic status except BMI and baseline routine
chemistry results. We aimed to elucidate the difference in
fasting serum glucose level or uric acid level according to
BMI, but it was not significant as the number of subjects
was relatively small (Table 4). A larger scaled study is also
required to explain the exact mechanism of the association
between BMI and post-THW hypercholesterolemia.
This study has several limitations. First of all, this
was a retrospective study analyzing relatively few subjects,
and, therefore, a multifaceted study evaluating the effect
of hypothyroidism on various aspects of lipid metabolism,
including cholesterol synthesis, clearance, and efflux, must be
performed in the future to further clarify the exact molecular
mechanism of the effect of BMI on dyslipidemia caused by
thyroid hormone deficiency in athyreotic patients. We also
could not include thorough lipid profile data at time point
P0 except total cholesterol level, because only routine chem-
istry exam was performed for preoperative blood test (P0)
according to the surgical preparation protocol of our institute.
The data about thyroid function tests and lipid profile at a
time point between surgery and the start of thyroid hormone
withdrawal also could not be analyzed in this retrospective
study because they were not routinely performed in our
institute. There might be some difference between baseline
preoperative lipid profile and the lipid profile immediately
before the start of thyroid hormone withdrawal which
must be accompanied with suppressed thyrotropin level by
supraphysiological levothyroxine replacement. This must be
further evaluated in a prospective and more controlled study.
Furthermore, the most lipid abnormalities accompanied by
short-term acute hypothyroidism are reversible with L-T4
replacement, so the long-term clinical implication of this
study should also be evaluated through additional prospec-
tive studies. Nonetheless, this study found a statistically
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significant association between BMI and post-THW hyperc-
holesterolemia despite a small sample size of 61 patients; since
THW is being more widely employed (both diagnostically
and therapeutically) as part of postsurgical management of
thyroid cancer, attention needs to be paid to post-THW lipid
profile abnormality and its long-term health outcome, at least
in patients with underlying metabolic derangements, such as
overweight and insulin resistance.
In conclusions, BMI is an independent determining
factor for serum cholesterol level after THW in thyroidec-
tomized patients. Overweight patients who have under-
gone total thyroidectomy may be more susceptible to the
adverse metabolic effects of thyroid hormone deficiency.
These patients must be considered to be in higher risk of dys-
lipidemiawhen exposed to hypothyroid and athyreotic status.
Maintaining BMI and thyroid hormonal status in appropriate
range needs to be stressed more in this group during the
postoperative follow-up periods of thyroid cancers.
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